Table 2.
Overall cohort survival analysis utilizing competing risks regression for CSS and propensity score matching and age-stratified analysis for early-stage kidney cancer patients 65 years or older, SEER-Medicare 1995–2007.
| OVERALL COHORT
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Survivalc | Groupd | Unadjusted | Adjusteda | Propensity Score Matchedb | ||||||
| HR | (95% CI) | p-value | HRa | (95% CI) | p-value | HRb | (95% CI) | p-value | ||
| OS | PN vs NSM | 0.25 | (0.22–0.29) | <0.01 | 0.40 | (0.34–0.46) | <0.01 | 0.36 | (0.30–0.44) | <0.01 |
| RN vs NSM | 0.36 | (0.32–0.40) | <0.01 | 0.50 | (0.45–0.56) | <0.01 | 0.50 | (0.42–0.58) | <0.01 | |
| PN vs RN | 0.70 | (0.63–0.78) | <0.01 | 0.80 | (0.71–0.90) | <0.01 | 0.86 | (0.75–0.99) | 0.04 | |
| CSS | PN vs NSM | 0.24 | (0.16–0.36) | <0.01 | 0.42 | (0.27–0.64) | <0.01 | 0.34 | (0.19–0.59) | <0.01 |
| RN vs NSM | 0.44 | (0.34–0.58) | <0.01 | 0.62 | (0.46–0.85) | <0.01 | 0.60 | (0.40–0.89) | <0.01 | |
| PN vs RN | 0.55 | (0.39–0.77) | <0.01 | 0.67 | (0.47–0.95) | 0.03 | 0.62 | (0.42–0.93) | 0.02 | |
|
| ||||||||||
|
AGE-STRATIFIED ANALYSIS
| ||||||||||
| <75 Years Old | 75–<80 Years Old | ≥80 Years Old | ||||||||
| HRa | (95% CI) | p-value | HRa | (95% CI) | p-value | HRa | (95% CI) | p-value | ||
|
| ||||||||||
| OS | PN vs NSM | 0.44 | (0.35–0.56) | <0.01 | 0.33 | (0.25–0.43) | <0.01 | 0.36 | (0.27–0.48) | <0.01 |
| RN vs NSM | 0.51 | (0.42–0.63) | <0.01 | 0.38 | (0.30–0.48) | <0.01 | 0.55 | (0.46–0.66) | <0.01 | |
| PN vs RN | 0.87 | (0.73–1.02) | 0.09 | 0.86 | (0.70–1.07) | 0.80 | 0.65 | (0.50–0.84) | <0.01 | |
| CSS | PN vs NSM | 0.64 | (0.28–1.46) | 0.29 | 0.27 | (0.12–0.58) | <0.01 | 0.41 | (0.19–0.91) | 0.03 |
| RN vs NSM | 0.86 | (0.42–1.74) | 0.67 | 0.40 | (0.22–0.73) | <0.01 | 0.68 | (0.45–1.04) | 0.08 | |
| PN vs RN | 0.75 | (0.45–1.26) | 0.28 | 0.66 | (0.34–1.30) | 0.23 | 0.60 | (0.29–1.26) | 0.18 | |
Cox regression adjusted for age, sex, race, residence, marital status, Charlson comorbidity index, baseline end-stage renal disease, tumor size, and year of diagnosis; Fine and Gray competing risks regression used to obtain subhazard ratios for CSS; similar results obtained using propensity score matching for age-stratified cohort
One-to-one propensity score matching balancing age, sex, race, residence, marital status, Charlson comorbidity index, baseline end-stage renal disease, and tumor size
OS: Overall survival; CSS: Kidney cancer-specific survival
Charlson comorbidity index